HK1213923A1 - 促卵激素 /胞溶域融合構造體和其製備及使用方法 - Google Patents

促卵激素 /胞溶域融合構造體和其製備及使用方法

Info

Publication number
HK1213923A1
HK1213923A1 HK16101924.1A HK16101924A HK1213923A1 HK 1213923 A1 HK1213923 A1 HK 1213923A1 HK 16101924 A HK16101924 A HK 16101924A HK 1213923 A1 HK1213923 A1 HK 1213923A1
Authority
HK
Hong Kong
Prior art keywords
fsh
follicle
making
methods
same
Prior art date
Application number
HK16101924.1A
Other languages
English (en)
Inventor
Carola Leuschner
Hector Alila
William Hansel
Original Assignee
Esperance Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperance Pharmaceuticals Inc filed Critical Esperance Pharmaceuticals Inc
Publication of HK1213923A1 publication Critical patent/HK1213923A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK16101924.1A 2012-11-15 2016-02-22 促卵激素 /胞溶域融合構造體和其製備及使用方法 HK1213923A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261726935P 2012-11-15 2012-11-15
PCT/US2013/070093 WO2014078533A1 (en) 2012-11-15 2013-11-14 Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same

Publications (1)

Publication Number Publication Date
HK1213923A1 true HK1213923A1 (zh) 2016-07-15

Family

ID=50731688

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101924.1A HK1213923A1 (zh) 2012-11-15 2016-02-22 促卵激素 /胞溶域融合構造體和其製備及使用方法

Country Status (11)

Country Link
US (1) US20140161767A1 (zh)
EP (1) EP2920212A4 (zh)
JP (1) JP2016506373A (zh)
KR (1) KR20150122625A (zh)
CN (1) CN105073779A (zh)
AU (1) AU2013344701A1 (zh)
BR (1) BR112015010943A2 (zh)
CA (1) CA2910311A1 (zh)
HK (1) HK1213923A1 (zh)
IL (1) IL238654A0 (zh)
WO (1) WO2014078533A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006321593B2 (en) * 2005-12-07 2012-10-04 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens
BR112015009752A2 (pt) 2012-10-30 2017-07-11 Esperance Pharmaceuticals Inc conjugados de anticorpo/fármaco e métodos de uso
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
HUE054673T2 (hu) * 2014-10-02 2021-09-28 Wistar Inst Rák kezelésére szolgáló eljárások és készítmények
WO2016073456A1 (en) * 2014-11-04 2016-05-12 The Trustees Of The University Of Pennsylvania Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor
IT201600101870A1 (it) * 2016-10-11 2018-04-11 Abresearch Srl Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia del neuroblastoma
EP3525810A2 (en) * 2016-10-11 2019-08-21 Oncogreen Therapeutics SA Ligands of the fsh hormone receptor in the diagnosis and treatment of tumors
IT201600101852A1 (it) * 2016-10-11 2018-04-11 Abresearch Srl Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia dei tumori
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN109957580A (zh) * 2019-05-07 2019-07-02 西北农林科技大学 一种表达人促卵泡生长激素（fsh）的方法
CN115768455A (zh) * 2020-03-26 2023-03-07 A28治疗公司 溶解结构域融合构建体、检查点抑制剂、以及制造和使用它们的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US20050287120A1 (en) * 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
US7122181B2 (en) * 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
WO2004042015A2 (en) * 2002-11-01 2004-05-21 Mayo Foundation For Medical Education And Research Methods and vectors for controlling gene expression
DK2252627T3 (en) * 2008-01-24 2017-08-14 Esperance Pharmaceuticals MERGER CONSTRUCTION WITH LYTIC DOMAIN AND METHOD FOR PRODUCING AND USING SAME.
CN102227503B (zh) * 2008-09-26 2015-10-21 托卡根公司 重组载体
WO2012050892A2 (en) * 2010-09-29 2012-04-19 Esperance Pharmaceuticals, Inc. Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors

Also Published As

Publication number Publication date
US20140161767A1 (en) 2014-06-12
CA2910311A1 (en) 2014-05-22
AU2013344701A1 (en) 2015-05-28
EP2920212A4 (en) 2016-07-27
WO2014078533A1 (en) 2014-05-22
BR112015010943A2 (pt) 2017-08-22
EP2920212A1 (en) 2015-09-23
JP2016506373A (ja) 2016-03-03
CN105073779A (zh) 2015-11-18
KR20150122625A (ko) 2015-11-02
IL238654A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
HK1213923A1 (zh) 促卵激素 /胞溶域融合構造體和其製備及使用方法
IL272279A (en) Chimeric antigen receptor and methods of using it
HK1213481A1 (zh) 抗體構建體及其使用方法
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
SG11201604719WA (en) Dna antibody constructs and method of using same
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
EP2862163A4 (en) METHOD AND NODE FOR ACTIVATING AND MANUFACTURING INPUTS FOR APPLICATION
HK1203161A1 (zh) 肽和使用該肽的方法
EP2938632A4 (en) ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE
SG11201507359SA (en) Flavivirus neutralizing antibodies and methods of use thereof
EP2951217A4 (en) SURFACTANTS AND METHODS OF MAKING AND USING THEM
HK1209432A1 (zh) 抗鋸齒蛋白抗體及使用方法
SG11201505891VA (en) Catalyst compositions and methods of making and using same
HK1206249A1 (zh) 人自分泌運動因子 的抗體及其使用方法
EP2975062A4 (en) PREPARATION AND USE OF DIMERIZED FUSION PROTEIN
EP2988778A4 (en) CLOSTRIDIUM DIFFICILE IMPREGENT AND METHOD OF USE
ZA201406392B (en) Post-accident network probe and method of using the same
EP2804564A4 (en) COUPLING DEVICES AND METHODS OF USE
EP2951289A4 (en) PLAZENTAMEMBRANPA PREPARATION AND METHOD FOR THE PRODUCTION AND USE THEREOF